FdaApplication
BLA 761040
Identifiers
- fda_app_no: BLA761040
Properties
| Property | Value |
|---|---|
| applicant_name | Wyeth Pharmaceuticals LLC |
| application_type | BLA |
| approval_date | 2017-08-17 |
Revenue by product
BESPONSA
| Period | Revenue |
|---|---|
| Q4 2023 | $65.0M |
| Q3 2023 | $54.0M |
| Q2 2023 | $59.0M |
| Q1 2023 | $58.0M |
| Q4 2022 | $55.0M |
| Q3 2022 | $55.0M |
| Q2 2022 | $58.0M |
| Q1 2022 | $51.0M |
| Q4 2021 | $47.0M |
| Q3 2021 | $50.0M |
| Q2 2021 | $45.0M |
| Q1 2021 | $50.0M |
| Q4 2020 | $48.0M |
| Q3 2020 | $44.0M |
| Q2 2020 | $46.0M |
| Q1 2020 | $44.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BESPONSA | INOTUZUMAB OZOGAMICIN | 0.9MG | For Injection |
1 product